Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Ketone-based hematopoietic agents developed at Toray

June 3, 1999

Licensing opportunity from Cornell Research Foundation: antidiabetic fagopyritols

June 3, 1999

Plant-based Novogen product increases HDL cholesterol

June 3, 1999

Squalene synthase inhibitor BMS-184494 tested in humans; spotlight on squalene synthase inhibitors

June 3, 1999

Orlistat as adjunct to hypocaloric diet reduces CVD risk factors in obesity

June 2, 1999

Small study indicates therapeutic potential of sildenafil in women with sexual arousal disorders

June 1, 1999

New cholesterol-binding agent on the road to launch in Japan

June 1, 1999

GW-0072, a novel PPARgamma receptor ligand with unique biological activities

May 31, 1999

Novel bicyclic compounds useful for lipid disorders, diabetes, obesity, etc.

May 28, 1999

Cephalon develops compounds for muscle wasting

May 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...